NW Natural Holdings Schedules Earnings Release and Conference Call for Friday, November 3
PORTLAND, Ore.–(BUSINESS WIRE)–Northwest Natural Holding Company (NYSE: NWN) (NW Natural Holdings) announced today it will issue its third quarter and... Read more.
Q4 DRAM Contract Prices Set to Rise, With Estimated Quarterly Increase of 3-8%, Says TrendForce
TAIPEI, Taiwan–(BUSINESS WIRE)–#DDR4—TrendForce reports indicate a universal price increase for both DRAM and NAND Flash starting in the fourth... Read more.
UnitedHealth Group Reports Third Quarter 2023 Results
Revenues of $92.4 Billion Grew 14% Year-Over-Year Earnings from Operations Grew 14% Cash Flows from Operations were $6.9 Billion Earnings were $6.24 Per Share, Adjusted... Read more.
LEO Pharma Presents Phase 3 Results of Delgocitinib Cream for Adults with Moderate to Severe Chronic Hand Eczema (CHE) at EADV 2023
NOT FOR UK USE – NOT INTENDED FOR UK MEDIA Phase 3 DELTA 2 results demonstrated that delgocitinib cream provided statistically significant improvements in both... Read more.
LEO Pharma Presents New Long-Term Data on Use of Adtralza® (tralokinumab) to Treat Moderate-to-Severe Atopic Dermatitis (AD)
NOT FOR UK USE – NOT INTENDED FOR UK MEDIA A post hoc four-year interim subgroup analysis of the ongoing ECZTEND open-label extension trial assessed whether continuous... Read more.
Almirall’s Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1
These primary data of the ADvantage study were presented today at EADV Congress A total of 18 lebrikizumab abstracts were disclosed at EADV, including new data on... Read more.
AM Best Europe Insurance Market Briefing to Examine State of Industry Amid Escalating Challenges; Beazley CEO to Deliver Keynote
LONDON–(BUSINESS WIRE)–#insurance—AM Best will host its annual Europe Insurance Market and Methodology Briefings on Tuesday, 7 November 2023, from... Read more.
SES Appoints Adel Al-Saleh as CEO
LUXEMBOURG–(BUSINESS WIRE)–Regulatory News: SES, a leading provider of global content connectivity solutions, today announced that Adel Al-Saleh has... Read more.
Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183, Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Plaque Psoriasis at EADV Congress 2023
TOKYO–(BUSINESS WIRE)–Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi) today announced... Read more.
Alpaca and Japan’s SBI Holdings Announce Partnership and USD15 Million Strategic Investment to Accelerate Alpaca’s Asian Business
Alpaca Surpasses 150 Businesses Launching on its Brokerage Platform and Prepares for Accelerated Growth With Strategic Partners For Each Key Region SAN MATEO, Calif.–(BUSINESS... Read more.